Thursday's Health Winners & Losers

Shares of Tenet Healthcare (THC Quote) dipped 1.8% Thursday after the company reached a $900 million settlement with the Justice Department related to its alleged over-billing of Medicare.

Tenet agreed to pay $725 million to settle federal investigations into its transactions with the federal health insurance program before 2003, and will waive its right to pursue $175 million in past Medicare payments.

While the company did acknowledge that it "made mistakes in its conduct before 2003," the settlement means investigations will cease and no conclusion will be reached on whether Tenet broke the law. Shares of Tenet fell 13 cents to $7.11.

Pharmaceuticals giant Pfizer(PFE Quote) plans to introduce its own generic version of its branded antidepressant Zoloft. Shares of Pfizer gained 34 cents, or 1.5%, to $23.24.

Generic-drug maker Teva Pharmaceutical(TEVA Quote), which received Food and Drug Administration approval to market a generic version of Zoloft, fell $1.05, or 3.3%, to $31.29.

The company had already been dealing with Merck's(MRK Quote) decision to undercut Teva with its own generic version of the cholesterol drug Zocor and an ongoing patent infringement battle with Abbott (ABT Quote) over a generic version of the antibiotic Biaxin.

Bristol-Myers Squibb(BMY Quote) was up 1.8% following the company's announcement Wednesday that it received Food and Drug Administration approval to market its new drug Sprycel for a blood cancer known as Philadelphia chromosome-positive acute lymphoblastic leukemia in patients who did not adequately respond or could not tolerate other treatments. Bristol says the drug should be available for sale nationwide within days.

The FDA also granted Sprycel accelerated approval for the treatment of adults with the blood disease chronic myeloid leukemia with resistance or intolerance to prior therapy, including Novartis' (NVS Quote) blockbuster drug Gleevec. Accelerated approval allows a company to submit its application for a drug's approval on a rolling basis instead of the traditional method of submitting it all at once. Bristol shares traded up 46 cents to $25.70.